D’Amico concluded that remigromig is the first biologic with a novel mechanism of action that demonstrated a noninferior ...
Community oncology practices need to move unstructured data into accessible fields before artificial intelligence (AI) can support clinical decisions, and they can judge AI purchases by whether a tool ...
AI tools are streamlining retina practice, but adoption depends on fitting them into real-world workflows.
A sarcoma-specific indocyanine green protocol using a signal-to-background ratio cut point of 1.67 identified 14 of 15 ...
Weill Cornell's Mateo Mejia Saldarriaga, MD, discusses patient preference for on-body isatuximab and how to sequence CAR T ...
The Bimatoprost Drug Pad-IOL (BIM-IOL) System, developed by SpyGlass Pharma, uses 2 drug-eluting pads attached to the lens to ...
A vote taken by the sound of applause rang out during an early morning session at (AAO) 2026 annual meeting, where 2 experts discussed the pros and cons of using complement inhibitors to treat ...
In the pivotal BRUNELLO trial, both doses of remigromig, a Wnt pathway agonist, were noninferior to ranibizumab for diabetic ...
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help ...
Artificial intelligence (AI) could help close gaps in eye care for underserved communities, but only if the tools reach the ...
Access to emergency eye care remains a public health challenge, with gaps that affect patients and communities across the ...
At the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, Michael F. Chiang, MD, director of the National Eye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results